natgillin/translations-raw huggingface dataset:
a drive system configured to control said extraction device, said control device and said agitation device, said system being designed to enable the uniform mixing of the extracted blood component and of the additive solution in said collecting satellite bag. 
pogonski sustav predviđen za izdavanje naredbi spomenutom uređaju (14) za ekstrakciju, spomenuti kontrolni uređaj (15) i spomenuti uređaj za mućkanje (16), spomenuti sustav se projektira da omogući ujednačeno miješanje ekstrahirane komponente krvi i aditivnog rastvora u spomenutoj zbirnoj satelitskoj vreći (3).
at least one acidifying agent comprises citric acid; and 
najmanje jedno sredstvo za zakiseljavanje je odabrano iz limunske kiseline i fosforne kiseline;
wherein the lateral displacement of the tip at the distal end point of the tip is approximately in a range of 40 to 200 microns; 
Fakoemulzifikacijski vrh prema zahtjevu 1, naznačen time, da je bočno premještanje vrha na točki distalnog kraja (106) od vrha, otprilike u rasponu od 40 do 200 mikrona.
The pharmaceutical dosage form for use according to any of the preceding claims, which contains the pharmacologically active agent according to general formula (I) in an amount that is sub-therapeutic with regard to a single administration of the dosage form. 
Farmaceutski oblik doziranja za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time što je nociceptivna bol odabrana od akutne nociceptivne boli i kronične nociceptivne boli.
Viral infection to be treated by the method of the invention can be mediated by, for example, human immunodeficiency virus (HIV), hepatitis C virus (HCV), herpes simplex virus type I (HSV-1) or the Severe Acute Respiratory Syndrome (SARS) virus. 
Antitijelo ili antigen-vežući dio prema patentnom zahtjevu 13 za uporabu u postupku za tretman prema patentnom zahtjevu 13, gdje je virusna infekcija posredovana preko virusa humane imunodeficijencije (HIV), virusa hepatitisa
The method of Embodiment 1 further comprising resolving the compound of formula (I), or a pharmaceutically acceptable salt thereof, under suitable conditions, to yield a compound of formula (I-S): or a pharmaceutically acceptable salt thereof, and a compound of formula (I-R): or a pharmaceutically acceptable salt thereof. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se dodatno sastoji u razdvajanju spoja formule (1), ili njegove farmaceutski prihvatljive soli, u obliku smjese enantiomera, u uvjetima pogodnim za dobivanje spoja formule (I-$): ili njegove farmaceutski prihvatljive sol, i spoja formule (I-R):
A pharmaceutical composition according to claim 2 or 3, comprising a monoclonal antibody or binding fragment thereof which specifically binds TcdB comprising a heavy chain wherein the variable domain of the heavy chain comprises at least one of a CDR having the sequence given in SEQ ID NO:124 for CDR-H1, a CDR having the sequence given in in SEQ ID NO:125 for CDR-H2 and a CDR having the sequence given in SEQ ID NO:126 for CDR-H3 and a light chain wherein the variable domain of the light chain comprises at least one of a CDR having the sequence given in SEQ ID NO:121 for CDR-L1, a CDR having the sequence given in in SEQ ID NO:122 for CDR-L2 and a CDR having the sequence given in SEQ ID NO:123 for CDR-L3. 
Farmaceutski pripravak prema zahtjevu 2 ili 3, naznačen time da sadrži monoklonsko protutijelo ili njegov vezni fragment koji specifično veže TcdB koji sadrži teški lanac pri čemu varijabilna domena teškog lanca sadrži najmanje jedan CDR koji ima sekvencu danu u SEQ ID NO:124 za CDR-H1, CDR koji ima sekvencu danu u SEQ ID NO:125 za CDR-H2 i CDR koji ima sekvencu danu u SEQ ID NO:126 za CDR-H3 1 laki lanac pri čemu varijabilna domena lakog lanca sadrži najmanje jedan CDR koji ima sekvencu danu u SEQ ID NO:121 za CDR- L1, CDR koji ima sekvencu danu u SEQ ID NO:122 za CDR-L2 i CDR koji ima sekvencu danu u SEQ ID NO: 123 za CDR-L3.
According to one embodiment, the antibody according to the invention binds to the A-B peptides aggregated into senile plaques and not to the diffuse deposits of A-B peptides. 
- < navedeno protutijelo se veže na A-8 peptide nakupljene u senilnim plakovima i ne na difuzne naslage A-f peptida.
The present invention is based on the development of a purification process for IL-18 binding protein (IL-18BP). 
Ovaj izum se bazira na razvijanju procesa za pročišćavanje proteina IL-18BP.
The combination of claim 1 or claim 3 wherein the cancer is metastatic, refractory to a standard first-line cancer treatment, or relapsed. 
Kombinacija iz patentnog zahtjeva 1 ili patentnog zahtjeva 3, pri čemu je karcinom metastatski, refraktoran na standardnu prvu liniju liječenja karcinoma, ili u relapsu.
The improvement of claim 8, wherein the receiver includes means for actuating an alarm when wireless communication between the transmitter and the receiver is broken. 
2, Sustav u skladu s patentnim zahtjevom 1, naznačen time da prijemnik sadrži način za pokretanje alarma kad je prekinuta bežična komunikacija između odašiljača i prijemnika.
Only small amounts of the metabolite M2 were formed. 
Stvarale su se samo male količine metabolita M2.
The compound or composition for use of claim 12, wherein the cancer is selected from the group consisting of breast cancer, ovarian cancer, a tumor of the endometrium, cervical carcinoma, lung cancer, prostate cancer, pancreatic cancer, an hematological cancer, a leukemia, colon cancer, a bowel tumor, a glioblastoma, a lymphoma, and a melanoma. 
Spoj ili pripravak za primjenu prema zahtjevu 12, naznačen time, što je rak odabran iz skupine koja se sastoji od raka dojke, raka jajnika, tumora endometrija, karcinoma vrata maternice, raka pluća, raka prostate, raka gušterače, hematološkog karcinoma, leukemije, raka debelog crijeva, tumora crijeva, glioblastoma, limfoma i melanoma.
The phenyl-substituted lower alkyl groups are exemplified by the lower alkyl groups as mentioned above having one phenyl group as a substituent. 
(Ald) fenil-supstituiranu skupinu niži alkil s halogen-supstituiranom skupinom (skupinama) niži alkil kao supstituentom (s) na fenilnoj skupini,
According to another preferred aspect, said pharmaceutical composition comprises between 1 and 8 mg of 5-HT3 antagonist per dosage unit for adults and corresponding doses according to body weight for children and babies. 
Farmaceutski pripravak prema bilo kojem od zahtjeva 3 do 7 naznačen time što spomenuti farmaceutski pripravak sadržava između 1 i 8 mg antagonista inhibitora 5-HT:3 po dozirnoj jedinici za odrasle i odgovarajuće doze prema tjelesnoj masi za djecu i dojenčad.
Then 8.7 ml NaOH 1 molar is slowly added at RT within 20 minutes. 
Zatim se polagano na RT unutar 20 minuta doda 8,7 ml 1M NaOH.
Compound according to claim 1 wherein R1 is the following group: 
Spoj u skladu s patentnim zahtjevom 1, gdje R1 je sljedeća skupina:
in a fourth step the formed crystallized product is obtained. 
- < učetvrtom koraku dobije se formirani kristalizirani produkt.
The cytotoxic agent according to claim 9, wherein the antibody is conjugated to a cytotoxic substance via a linker. 
Citotoksično sredstvo u skladu s patentnih zahtjeva 3 do 4, naznačeno time što je protutijelo konjugirano s citotoksičnom tvari preko spojnice.
The lighting unit according to claim 1 characterized in that the majority of said LED devices included in said lighting unit emit warm white light. The lighting unit according to claim 1 characterized in that the minority of said LED devices placed in said lighting unit emit coloured light. 
Lampa prema bilo kojem od prethodnih zahtjeva naznačena time što većina LED uređaja (3) u toj lampi emitira toplo bijelo svjetlo 1 po izboru manji broj LED uređaja u toj lampi emitira obojeno svjetlo.
In another embodiment, the aqueous formulation comprises 700 U/ml to 1000 U/mL of insulin glargine. 
Vodena formulacija u skladu s patentnim zahtjevom 3, naznačena time što sadrži 0,2 ug do 1 ug liksisenatida po jedinici inzulin glargina.
"acyl", as used herein, pertains to a -C(=O)R group, wherein R is H, a C1-7 alkyl group, a C3-20 heterocyclyl group, or a C5-20 aryl group; 
"acil", kako se ovdje koristi, odnosi se na -C(=0)R skupinu, pri čemu R je H, C;; alkilna skupina, C3.20 heterociklilna skupina, ili C5.29 arilna skupina;
a utility consumption related data element memory comprising a plurality of storage locations configured to store data elements indicative of the consumption of said utilities measured at a time of storing respective ones of said data elements; 
- sredstva za pohranu podatkovnih elemenata vezanih uz potrošnju (CB) koje se sastoji od velikog broja lokacija za pohranu (Nx, Nx+1) za pohranu podatkovnog elementa vezano uz potrošnju navedenih komunalnih usluga za koju je indikativna i koja je izmjerena u vrijeme pohrane dotičnog podatkovnog elementa;
The process according to claim 5, wherein the intrinsic viscosity of the post-consumer PET resin is higher than 0.6 ml/g, preferably higher than 0.65 ml/g, and the viscosity of the post-consumer resin is increased by means of chain extending, reactive additives during the compounding process. 
Postupak prema patentnom zahtjevu 5, naznačen time da je intrinzična viskoznost post-potrošačke PET smole viša od 0.6 ml / g, poželjno viša od 0.65 mL / g, te se viskoznost post-potrošačke smole povećava pomoću produženog lanca, reaktivnih aditiva tijekom procesa miješanja.
applying the plurality of fibre elements to at least one side of the base film; and 
(iii) primjena više elemenata vlakana na barem jednu stranu osnovne folije, i
The pharmaceutical combinations according to the invention may contain (a) and (b) in the case of formoterol, for example, in a ratio by weight (b):(a) ranging from 1: 10 to 300:1, preferably from 1: 5 to 200:1. preferably 1: 3 to 150:1, more preferably from 1:2 to 100:1. 
Farmaceutske kombinacije sukladno predmetnom izumu mogu sadržavati (a) i (b) u slučaju budesonida, na primjer u težinskom omjeru (b):(a) u rasponu od 1:10 do 50:10, poželjno od 1:5 do 10:1, poželjno od 1:4 do 5:1, a najpoželjnije od 1:2 do 2:1.
The organic phase is prepared by dispersing the active opioid antagonist in the organic solvent(s). 
Sredstvo za transdermalno davanje prema zahtjevu 1, naznačeno time da je opioidni antagonist u obliku stabilnih kristalnih čestica.
A method according to claim 8, wherein the groove (28) is formed on a radially outer flange (29) of the cap (20). 
Postupak u skladu s patentnim zahtjevom 8, naznačen time, da je utor (28) oblikovan na radijalnoj vanjskoj prirubnici (29) poklopca (20).
Use according to claim 9, characterized in that the auto-immune disease is rheumatoid arthritis, glomerulonephritis, multiple sclerosis, Crohn's disease, ulcerative colitis, systemic lupus erythematosus or psoriasis. 
Uporaba sukladno patentnom zahtjevu 9, naznačena time, da je autoimuna bolest reumatoidni artritis, glomeruloneftitis, multipla skleroza, Crohnova bolest, ulcerozni kolitis, sistemski lupus eritematosus ili psorijaza. t>&
extending downwards therefrom, a short serrated cylindrical wall 216 . 
pruža se prema dolje od njega, je kratka nazubljena valjkasta stijenka 216.
Use of a combination of a renin inhibitor and an efflux protein inhibitor, wherein the efflux protein inhibitor is PSC833, for the manufacture of a medicament, wherein the efflux protein inhibitor improves the bioavailability of a renin inhibitor. 
Uporaba kombinacije inhibitora renina i inhibitora istjecanja proteina, pri čemu inhibitor istjecanja proteina je PSC833, naznačena time, da se koristi pripravu lijeka, pri čemu inhibitor istjecanja proteina poboljšava bioraspoloživost inhibitora renina,
The compound according to the above-mentioned [2] wherein R1 is a C1-6 alkyl group optionally having one 3- to 8-membered monocyclic nonaromatic heterocyclic group optionally having 1 to 3 C1-6 alkyl groups, or 
Spoj prema zahtjevu 2, naznačen time, da R/ je sljedeće: (1) Crs alkil-skupina koja opcijski ima jednu 3-članu do 8-članu monocikličku nearomatsku heterocikličku skupinu koja opcijski ima jednu do tri C14 alkil-skupine, ili (2) C3.s cikloalkil-skupina.
In one aspect of the present invention, the GPR119 agonist is an agonist of human GPR119. 
Pripravak u skladu sa zahtjevom 1, naznačen time, da GPR119 agonist je agonist humanog GPR119.
silica particles comprising said nucleotide or nucleoside analogue reverse transcriptase inhibitor and having a maximum diameter of ≤1,000 um, as such or as a suspension, with 
čestica silike koje sadrže navedeni nukleotidni ili nukleozidni analog inhibitor reverzne transkriptaze i koje imaju maksimalni promjer od ≤ 1 000 µm, kao takvih ili kao suspenzije, sa
The double stranded RNAi agent of claim 1, wherein the dsRNA comprises: 
Dvolančano RNAi sredstvo prema zahtjevu 1, naznačeno time da dsRNA sadrži:
1 . Comparative stability study. 
Slika 1. - Usporedno ispitivanje stabilnosti.
The method according to claim 1, comprising the further step of subjecting pozzolan particles to a pre-classification to separate a fraction with a retention on the sieve 45 microns which is at least 99% and in that the oversized particles are grinded to a fineness with a retention on the sieve 30 microns which is less than 5%. 
Postupak prema patentnom zahtjevu 1, naznačen time što se pucolan podvrgava pred-klasifikaciji kako bi se odvojila frakcija s retencijom na situ od 45 mikrona koja je najmanje 99 % i time što se prevelike čestice usitnjavaju do finoće s retencijom na situ od 30 mikrona koja je manja od 5 %.
A compound selected from the group consisting of: and pharmaceutically acceptable salts thereof. 
Spoj, naznačen time, da je odabran iz skupine koja se sastoji od:
Blood glucose was analyzed by the glucose oxidation method with a Glucometer Elite (Bayer). 
Glukoza u krvi je analizirana pomoću postupka oksidacije glukoze sa glukometrom Elite (Bayer).
Hard gelatin capsules may also contain the compound of the invention in combination with solid powdered ingredients such as lactose, saccharose, sorbitol, mannitol, potato starch, corn starch, amylopectin, cellulose derivatives or gelatin. 
Kapsule od tvrde želatine mogu također sadržavati spoj iz ovoga izuma u kombinaciji s krutim praškastim sastojcima poput laktoze, saharoze, sorbitola, manitola, krumpirovog škroba, škroba iz kukuruza, amilopektina, derivata celuloze ili želatine.
In a more particular embodiment of the invention there is provided a polynucleotide encoding a therapeutic antibody heavy chain, which polynucleotide comprises the sequence set forth in SEQ ID No:35, 37, 39 or 42. 
12. Polinukleotid koji kodira teški lanac terapijskog protutijela, naznačen time što navedeni polinukleotid ima slijed iznijet u SEQ ID No:35, 37, 39 ili 42.
Falls, weight loss, and swallowing difficulties may be a problem during this stage and dementia becomes more obvious to the casual observer. 
Padovi, gubitak težine i teškoće s gutanjem mogu biti problem za vrijeme ovog stadija i demencija postaje očita i slučajnom promatraču.
An antibody directed against the extracellular part of Sortilin and capable of inhibiting binding of a pro-neurotrophin to a binding site on the Sortilin receptor, wherein the antibody is directed against a sequence having SEQ ID NO: 25, SEQ ID NO. 26, SEQ ID NO. 27 or SEQ ID NO. 28 for use in treatment of human neurodegenerative disorders. 
Protutijelo usmjereno prema izvanstaničnom dijelu Sortilina koje je sposobno inhibirati vezanje pro-neurotrofina za vezno mjesto receptora Sortilina, pri čemu se protutijelo veže za motiv vezanja za pro-neurotrofin u skladu sa SEQ ID NO:25, 26, 27 ili 28 ili za njegov fragment.
A method of coating a substrate according to any preceding claim, wherein the total dry film thickness of the antifouling coat (b) immediately after application is 30-500µm. 
Metoda premazivanja supstrata sukladno bilo kojem ranijem zahtjevu, naznačena time što ukupna debljina suhog filma antivegetativnog premaza (b) odmah nakon aplikacije iznosi 30-500 um.
A protein layer according to claim 1 or 2, wherein the protomers are heterologous with respect to the monomers. A protein layer according to claim 8, wherein the protein layer comprises protein protomers of two types, the first type of protomer comprising a first monomer which is a monomer of said first oligomer assembly belonging to a dihedral point group of order O, where O equals 3, 4, or 6, genetically fused to a second monomer which is a monomer of said second oligmer assembly, said second oligomer assembly being a hetrologous oligomer assembly belonging to a cyclic point group of order 2, and the second type of protomer comprising a third monomer which is a monomer of said second oligomer assembly, genetically fused to a fourth monomer which is a monomer of a third oligomer assembly, said third oligomer assembly belonging to a dihedral point group of order 2 or O. 
Postupak u skladu s patentnim zahtjevom 9, naznačen time, da su protomeri heterologni u odnosu na monomere, a proteinski sloj sadrži dva tipa proteinskih protomera, prva vrsta protomera sadrži prvi monomer, koji je monomer navedenog prvog skupa oligomera koji pripada dihedralnoj točkinoj grupi reda O, pri čemu O jest jednako 3, 4 ili 6, genetičkim putem spojen na drugi monomer, koji je monomer navedenog drugog skupa oligomera, pri čemu je navedeni drugi skup oligomera heterologni skup oligomera koji pripada cikličkoj točkinoj grupi reda 2, te druga vrsta protomera sadrži treći monomer, koji je monomer navedenog drugog skupa oligomera koji je genetičkim putem spojen na četvrti monomer, koji je monomer trećeg skupa oligomera, pri čemu treći skup oligomera pripada dihedralnoj točkinoj grupi reda 2 ili O.
wherein a scan pattern for scanning flags indicating non-zero coefficients of each subset is same with the scan pattern for scanning non-zero coefficients of each subset, and 
Uređaj prema zahtjevu 1, naznačen time da entropijski koder (130) kodira položaje ne-nultih koeficijenata i informacije za identifikaciju ne-nultih koeficijenata svakog pod-bloka.
naloxone is administered concurrently with a compound of Formula I. 
Spoj za uporabu sukladno patentnom zahtjevu 11, pri čemu se nalokson primjenjuje istodobno s tim spojem.
n is 0, 1, 2, or 3 and when n is 0 then a direct bond is intended; 
n je 0, 1, 2, ili 3 i kada n je 0 tada je namjeravana direktna veza;
Generation of Expression and Secretion System for Prokaryotic and Eukaryotic Cells 
Sustav ekspresije i sekrecije (54) Naziv izuma:
The use according to claim 3, wherein said extract is selected from among Mother Tincture, hydroalcoholic extract of the fresh plant and/or hydroalcoholic macerate of the fresh plant. 
Upotreba u skladu s patentnim zahtjevom 3, gdje se navedeni ekstrakt bira između matične tinkture, hidroalkoholnog ekstrakta svježe biljke i/ili hidroalkoholnog macerata svježe biljke.
According to the invention, the liquid preparation is used as a biological plant protection agent, biological plant strengthening agent or biological soil improvement agent, and if necessary it is diluted with water to the use concentration depending on the intended use. 
Uporaba prema zahtjevu 13, naznačena time da se tekući pripravak razrjeđuje s vodom do željene koncentracije za primjenu ovisno o namjeni.
Use of a compound as defined in any one of 1 to 12, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of a disorder mediated by inappropriate PI3-kinase activity. 
Upotreba kombinacije u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačena time što je kombinacija namijenjena proizvodnji medikamenta namijenjenog upotrebi u liječenju poremećaja uzrokovanog neodgovarajućom aktivnošću PI3-kinaze.
The oligonucleotide-based compound according to any one of claims 1 to 8 for use in a method for preventing a disease or disorder mediated by one or more proteins in a mammal at risk for developing the disease or disorder, wherein at least one of the oligonucleotides is complementary to single stranded RNA encoding the one or more proteins. 
Spoj na bazi oligonukleotida prema bilo kojem od zahtjeva 1 do 7 za upotrebu u postupku prevencije bolesti ili poremećaja posredovanog proteinom kod sisavca koji ima rizik za razvoj bolesti iki poremećaja, naznačen time da su oligonukleotidi komplementarni jednolančanoj RNA koja kodira protein.
The use of a composition comprising a dried, nonviable selenium-enriched yeast wherein the total selenium content of said yeast comprises two percent or less inorganic selenium in the manufacture of a medicament for treatment of diabetes under conditions such that the expression of Neurog3 is enhanced in said subject. 
Pripravak koji se koristi u proizvodnji lijeka sadrži suhi, neživi kvasac obogaćen selenom, naznačen time da u ukupnom sadržaju selena ima dva posto ili manje neorganskog selena, pri čemu je lijek formuliran za primjenu u subjektu pod uvjetom da se izražavanje komplement gena smanjuje u moždanoj kori tog subjekta u svrhu liječenja ili prevencije Alzheimerove bolesti.
The process according to claim 1, wherein the pH is adjusted to 2 to 7 with the acid. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, daje pH podešen od 2 do 6 s kiselinom.
An antibody or antigen-binding fragment according to claim 1, 2 or 3, which binds hIL-6R with an affinity at least 2-fold higher relative to binding monkey IL-6R. 
Antitijelo ili njegov fragment koji se veže na antigen prema zahtjevu 1, 2 ili 3, naznačen time, da se veže na hIL6R s afinitetom najmanje 1,5 puta većim u odnosu na afinitet vezivanja prema IL-6R majmuna.
Because anti-diabetic efficacy along with the liability of plasma volume expansion are common features of PPARY full agonists [Armstrong and King (2004), Mudaliar, et al (2003), Nesto et al, (2004)], our data suggest that compound of formula III could be an improved therapy for the treatment of type 2 diabetes compared to the currently marketed PPARY agonists 
Kako antidijabetična djelotvornost, uz nedostatak ekspanzije volumena plazme zajedničke su karakteristike punih agonista PPARy [Armstrong i King (2004.), Mudaliar i dr., (2003.), Nesto i dr., (2004.)], naši podaci ukazuju da bi spoj formule III mogao biti poboljšana terapija u liječenju dijabetesa tip 2, u usporedbi s agonistima PPARy trenutno prisutnim na tržištu.
Wind system (1) according to claim 1, characterised in that said recovering system (8) is made of a trellis-type structure. 
Vjetreni sustav (1) prema zahtjevu 2, naznačen time da se spomenuti spojler pokreće preko sustava sa samostalnim napajanjem.
The immunogenic composition according to claim 1 or claim 2 wherein X is the signal peptide of a protein selected from the group consisting of Flgl, NadA and pelB. 
Fuzijski protein u skladu s patentnim zahtjevom 1, naznačen time što je X signalni peptid iz proteina koji se bira iz skupine koju čine Flgl, NadA i pelB.
In step (c), a solution of a compound of the formula I is prepared in a suitable organic solvent. 
(c) priprave otopine spoja formule I u prikladnom organskom otapalu; R, (R);
The fastening system of claim 1 further comprising a nut retainer sized to allow the nut to float within the nut retainer. 
Sustav pričvršćivanja (1) u skladu s patentnim zahtjevom 1, naznačen time, da nadalje sadržava držač matice (16) veličine koja omogućava plutanje matice (14) unutar držača matice (16).
represents a hydrogen atom, a lower alkyl, a substituted lower alkyl, a higher alkyl, a substituted higher alkyl, a cycloalkyl, a cycloalkylalkyl, a lower alkoxy, a substituted lower alkoxy, a higher alkoxy, a substituted higher alkoxy, a cycloalkylalkoxy, an acyloxy, an acyl, an alkoxycarbonyl, a carboxamide or a cyano, 
predstavlja atom vodika, aril, supstituirani aril, alkil, cikloalkil ili cikloalkilalkil; predstavlja atom vodika, niži alkil, supstituirani niži alkil, viši alkil, supstituirani viši alkil, cikloalkil, cikloalkilalkil, niži alkoksi, supstituirani niži alkoksi, viši alkoksi, supstituirani viši alkoksi, cikloalkilalkoksi, aciloksi, acil, alkoksikarbonil, karboksamid ili cijano;
This compound can be synthesised using methods well known in the art, see for example, FR 1434172. 
Ovaj spoj može se sintetizirati postupcima dobro poznatim u struci; vidjeti primjerice dokument FR 1434172.